A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

Trial Profile

A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Imilecleucel-T (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms Abili-T
  • Sponsors EMD Serono; Opexa Therapeutics
  • Most Recent Events

    • 09 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 16 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
    • 16 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top